ES3053333T3 - Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders - Google Patents

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Info

Publication number
ES3053333T3
ES3053333T3 ES14731261T ES14731261T ES3053333T3 ES 3053333 T3 ES3053333 T3 ES 3053333T3 ES 14731261 T ES14731261 T ES 14731261T ES 14731261 T ES14731261 T ES 14731261T ES 3053333 T3 ES3053333 T3 ES 3053333T3
Authority
ES
Spain
Prior art keywords
compound
formula
disease
hyperkinetic movement
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14731261T
Other languages
English (en)
Spanish (es)
Inventor
Batalla Núria Gavaldà
Boronat Raúl Insa
Bolano Núria Reig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3053333(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Application granted granted Critical
Publication of ES3053333T3 publication Critical patent/ES3053333T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14731261T 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders Active ES3053333T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
ES3053333T3 true ES3053333T3 (en) 2026-01-21

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14731261T Active ES3053333T3 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Country Status (19)

Country Link
US (2) US9789072B2 (enExample)
EP (1) EP3010543B1 (enExample)
JP (1) JP6476174B2 (enExample)
KR (1) KR102254542B1 (enExample)
CN (1) CN105658238B (enExample)
AU (1) AU2014283319B2 (enExample)
BR (1) BR112015031835B1 (enExample)
CA (1) CA2915811C (enExample)
CL (1) CL2015003679A1 (enExample)
DK (1) DK3010543T3 (enExample)
ES (1) ES3053333T3 (enExample)
IL (1) IL243192B (enExample)
MX (1) MX366353B (enExample)
PL (1) PL3010543T3 (enExample)
PT (1) PT3010543T (enExample)
RU (1) RU2685502C2 (enExample)
SG (1) SG11201510451RA (enExample)
WO (1) WO2014202646A1 (enExample)
ZA (1) ZA201600312B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
RS66714B1 (sr) * 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
MX2020003421A (es) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease

Also Published As

Publication number Publication date
PT3010543T (pt) 2025-11-28
RU2685502C2 (ru) 2019-04-19
BR112015031835B1 (pt) 2022-12-13
BR112015031835A8 (pt) 2019-12-31
HK1223014A1 (en) 2017-07-21
US20160158167A1 (en) 2016-06-09
CA2915811C (en) 2021-08-31
CA2915811A1 (en) 2014-12-24
CL2015003679A1 (es) 2016-09-02
EP3010543B1 (en) 2025-11-05
NZ715951A (en) 2021-03-26
ZA201600312B (en) 2022-12-21
US9789072B2 (en) 2017-10-17
WO2014202646A1 (en) 2014-12-24
PL3010543T3 (pl) 2026-01-19
BR112015031835A2 (pt) 2017-07-25
EP3010543A1 (en) 2016-04-27
DK3010543T3 (da) 2025-12-01
AU2014283319A1 (en) 2016-02-11
JP2016522235A (ja) 2016-07-28
IL243192A0 (en) 2016-02-29
KR102254542B1 (ko) 2021-05-24
AU2014283319B2 (en) 2019-07-25
MX366353B (es) 2019-07-05
CN105658238B (zh) 2019-07-12
CN105658238A (zh) 2016-06-08
KR20160055121A (ko) 2016-05-17
SG11201510451RA (en) 2016-01-28
IL243192B (en) 2019-12-31
MX2015018040A (es) 2016-08-03
JP6476174B2 (ja) 2019-02-27
RU2016101152A (ru) 2017-07-24
US20180042869A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
ES2871027T3 (es) Inhibidores potentes de la epóxido hidrolasa soluble
AU2022256175B2 (en) Antimicrobial compounds, compositions, and uses thereof
ES2729713T3 (es) Compuestos tricíclicos, composiciones que los comprenden y usos de los mismos
PT1440709E (pt) Combinações que compreendem inibidores de cgmp-pde5
MX2015003608A (es) Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
CA3081500A1 (en) Therapeutic approaches for treating parkinson's disease
JP2025023120A (ja) d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
US20180042869A1 (en) Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders
CN110913851B (zh) 治疗外伤性脑损伤的组合物和方法
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
WO2009151744A1 (en) S-nitrosomercapto compounds and related derivatives
HK1223014B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
NZ715951B2 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
ES2642003T3 (es) Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2
US20240285777A1 (en) Inhibitors of ttbk1
JP2022501419A (ja) 鎮痛組成物
TH103569A (th) อนุพันธ์ของ6-ไพริมิดินิล-ไพริมิด-2-โอน
TH103568A (th) อนุพันธ์ของ 6-ไพริมิดินิล-ไพริมิด-2-โอนชนิดใหม่